SavedAdd your journal

Journals / Ege Tıp Dergisi / 2006 / Cilt: 45 - Sayı: 2

Somatostatin receptor 1 expression in hepatocellular carcinoma

Hepatosellüler karsinomlarda somatostatin reseptör 1 ekspresyonu

Gül YÜCE
Deniz NART
Yıldıray YÜZER
Ömer ÖZÜTEMİZ
Galip ERSÖZ
Ulus AKARCA
Yücel BATUR
Pages
115–120
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In our study, exhibition of negative correlation between SSTR1 expression and Kİ67 proliferation marker supports antiproliferative effect of somatostatin analogs.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Somatostatin is a neuropeptide that inhibits cell proliferation.
📊
Key Findings & Data:Somatostatin receptor 1 (SSTR 1) was applied by immunohistochemistry in paraffin sections of 53 hepatocellular carcinoma cases.
💡
Conclusion & Impact:In our study, exhibition of negative correlation between SSTR1 expression and Kİ67 proliferation marker supports antiproliferative effect of somatostatin analogs.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Somatostatin · Karsinom · hepatosellüler

Abstract

Somatostatin is a neuropeptide that inhibits cell proliferation. Although somatostatin analogs are used widely in hepatocellular carcinoma treatment, knowledge about malign hepatocyte receptor expression is not sufficient. Somatostatin receptor 1 (SSTR 1) was applied by immunohistochemistry in paraffin sections of 53 hepatocellular carcinoma cases. No correlation was found between morphological parameters and SSTR 1 positivity. Interestingly a close negative relationship was observed between Kİ67 and SSTR1. In our study, exhibition of negative correlation between SSTR1 expression and Kİ67 proliferation marker supports antiproliferative effect of somatostatin analogs.

Özet

Somatostatin, hücre proliferasyonunu inhibe eden bir nöropeptidtir. Somatostatin analoglarının hepatosellüler karsinomlarda yaygın olarak kullanılmasına rağmen malign hepatositlerin reseptör ekspresyonu hakkında bilinenler yeterli değildir. Elli üç hepatosellüler karsinom olgusunda parafin kesitlerde immunohistokimyasal olarak somatostatin reseptör 1 (SSTR1) uygulandı. SSTR1 pozitifliği ile morfolojik parametreler arasında bir korelasyon saptanamadı. An­cak, Kİ67 ile SSTR1 arasında anlamlı negatif ilişki görüldü. Çalışmamızda SSTR1 ekspresyonunun Kİ67 proliferasyon markeri ile negatif korelasyon göstermesi somatostatin analoglarının antiproliferatif etkisini desteklemiştir.

🔖

Cite This Article

YÜCE, G., NART, D., YÜZER, Y., ÖZÜTEMİZ, Ö., ERSÖZ, G., AKARCA, U., BATUR, Y. (2006). Somatostatin receptor 1 expression in hepatocellular carcinoma. Ege Tıp Dergisi, Cilt: 45 - Sayı: 2, 115–120. https://ajindex.com/articles/223322

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (5)

  1. Hofland LJ, Lamberts SWJ Pathophysiological Consequences of Somatostatin Receptor Internalisation and Resistance. Endocrine Reviews 2003; 24: 28 - 47. Mao JD, Wu P, Xia XH, et al. Correlation between expression of gastrin, somatostatin and cell apoptosis gene bcl-2/bax in large intestine carcinoma. World Journal of Gastroenterology 2005; 11 (5): 721-725.
  2. Corleto VD, Nasoniş S, Panzuto F, et al. Somatostatin receptor subtypes:basic pharmacology and tissue distribution. Digestive and Liver Disease 2004; 36: S8 - S16. Low J. The sonatostatin neuroendocrine system: physicology and clinical relevance in gastrointestinal and pancreatic disorders. Best Practice and Research Clinical Endocrinology and Metabolism 2004; 18: 607-622.
  3. Bousquet C, Guillermet J, Vernejoul F, et al. Somatostatin receptors and regulation of cell proliferation. Digestive and Liver Disease 2004; 36: S2 - S7. Dasgupta P.Somatostatin analoques: Multiple roles in cellular proliferation,neoplasia and angiogenesis. Pharmacology and Therapeutics 2004; 102: 61 - 85. Dasgupta P, Singh AT Mukherjee R. Lipophiliation of somatostatin analog RC-160 with the long chain fatty acid improves its anti-proliferative activity on human oral carcinoma cells in vitro. Life Sci 2000; 66: 1557-1570.
  4. Ferjoux J, Torrisani J, Buscail L, et al. Somatostatin Receptors and cancer: Antioncogenic role of sst2A. Advances in Oncology Eds. SWJ Lamberts and L Dogliotti. Bio Scientifica Ltd. 2002; pp3-15. Lasfer M, Vadrot N, Schally AV, et al. Potent induction of apoptosis in human hepatoma cell lines by targeted cytotoxic somatostatin a.naloque AN-238. Journal of Hepatology 2005; 42: 230 - 237. Pawlikowski M, Melen-Mucha G. Somatostatin analogs from new molecules to new molecules to new applications. Current Opinion in Pharmacology 2004; 4: 608 - 613. Blaker M. Schmmitz M.Gocht A, et al. Differential expression of somatostatin receptor subtypes in hepatocellular carcinomas. Journal of Hepatology 2004; 41:112-118.
  5. Jia WD, Xu GL Sun HC et al. Effect of octreotide on angiogenesis induced by hepatocellular carcinoma in vivo. Hepatobiliary Pancreat. Dis. Int 2003; 2: 404 - 409. Jia WD, Xu GL Xu RN et al. Octreotide acts as an antitumor angiogenesis compound and suppresses tumor growth in nude mice bearing human hepatocellular carcinoma xenografts. J.Cancer Res. Clin. Oncol 2003;129: 327 - 334. Buchan AM, Lin CY, Choi J Barber DL.Somatostatin acting at receptor subtype 1, inhibits Rho activity the assembly of actin strees fibers, a